Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01689987 | Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 18 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT01866293 | Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma | completed | Phase 1 / Phase 2 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT02655458 | Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma | completed | Phase 1 | 15 | Hearn Jay ChoOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT01393964 | Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function | completed | Phase 1 | 35 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 3, 2017 | clinicaltrials |
| NCT01042704 | Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma | completed | Phase 1 | 29 | Robert Redner, MDOTHER | 1 | Jul 31, 2017 | clinicaltrials |
| NCT00281983 | Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia | completed | Phase 1 / Phase 2 | 100 | German CLL Study GroupOTHER | 2 | Jul 24, 2017 | clinicaltrials |
| NCT01460420 | Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation(EMN-alloRIC) | completed | Phase 1 / Phase 2 | 49 | European Myeloma Network B.V.NETWORK | 4 | Jul 6, 2017 | clinicaltrials |
| NCT00001512 | Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00001572 | Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00058240 | Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00366418 | Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia | completed | Phase 1 | 4 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01786096 | A Safety Study of SGN-CD19A for Leukemia and Lymphoma | completed | Phase 1 | 92 | Seagen Inc.INDUSTRY | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00614042 | Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma | completed | Phase 1 | 96 | Aptevo TherapeuticsINDUSTRY | 1 | Jun 28, 2017 | clinicaltrials |
| NCT02381080 | Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy | completed | Phase 1 | 26 | Janssen Research & Development, LLCINDUSTRY | 3 | Jun 26, 2017 | clinicaltrials |
| NCT01406314 | SAP Depleter Dose Assessment Study in Patients | completed | Phase 1 | 17 | GlaxoSmithKlineINDUSTRY | 1 | Jun 9, 2017 | clinicaltrials |
| NCT00241358 | Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 92 | Washington University School of MedicineOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT00724568 | Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma(RVDD) | completed | Phase 1 / Phase 2 | 74 | University of Michigan Rogel Cancer CenterOTHER | 2 | Jun 2, 2017 | clinicaltrials |
| NCT00603447 | Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma | completed | Phase 1 | 84 | AmgenINDUSTRY | 2 | May 30, 2017 | clinicaltrials |
| NCT01980589 | A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects(CHAMPION 2) | completed | Phase 1 | 22 | AmgenINDUSTRY | 1 | May 30, 2017 | clinicaltrials |
| NCT00601718 | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 29 | University of WashingtonOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01582295 | XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease | completed | Phase 1 | 4 | Massachusetts General HospitalOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01432600 | Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide | completed | Phase 1 / Phase 2 | 80 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT03057418 | Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim | completed | Phase 1 | 7 | Biointegrator LLCINDUSTRY | 1 | May 23, 2017 | clinicaltrials |
| NCT00150462 | Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies | completed | Phase 1 | 48 | AmgenINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT01949532 | Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease | completed | Phase 1 | 26 | AmgenINDUSTRY | 3 | May 2, 2017 | clinicaltrials |
| NCT02072863 | A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 9 | AmgenINDUSTRY | 3 | May 2, 2017 | clinicaltrials |
| NCT01226849 | Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma(SGH652) | completed | Phase 1 | 6 | Singapore General HospitalOTHER | 1 | Apr 27, 2017 | clinicaltrials |
| NCT00446342 | Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies | completed | Phase 1 | 21 | Sunesis PharmaceuticalsINDUSTRY | 1 | Apr 11, 2017 | clinicaltrials |
| NCT01004991 | Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma | completed | Phase 1 / Phase 2 | 14 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 10, 2017 | clinicaltrials |
| NCT01323751 | Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma(ACY-1215) | completed | Phase 1 / Phase 2 | 120 | CelgeneINDUSTRY | 1 | Apr 6, 2017 | clinicaltrials |
| NCT00005988 | Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy | completed | Phase 1 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT02401295 | ATRA, Celecoxib, and Itraconazole as Maintenance | completed | Phase 1 | 1 | University of IowaOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01019174 | Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma(MM_LEN_DEX_CY) | completed | Phase 1 / Phase 2 | 40 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT01475058 | CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant | completed | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00460694 | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies(alloCIK) | completed | Phase 1 / Phase 2 | 24 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT01300026 | AMG 319 Lymphoid Malignancy FIH | completed | Phase 1 | 28 | AmgenINDUSTRY | 1 | Feb 9, 2017 | clinicaltrials |
| NCT00201682 | Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 36 | John ByrdOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT00233506 | A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated | completed | Phase 1 | 41 | University of IowaOTHER | 1 | Feb 6, 2017 | clinicaltrials |
| NCT01300247 | A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON) | completed | Phase 1 | 41 | Genentech, Inc.INDUSTRY | 1 | Feb 2, 2017 | clinicaltrials |
| NCT00633594 | Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 39 | SCRI Development Innovations, LLCOTHER | 1 | Jan 31, 2017 | clinicaltrials |
| NCT01029054 | Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma | completed | Phase 1 / Phase 2 | 53 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 30, 2017 | clinicaltrials |
| NCT02953808 | Phase 1 Study of GSK2315698 in Healthy Japanese Subjects | completed | Phase 1 | 18 | GlaxoSmithKlineINDUSTRY | 1 | Jan 19, 2017 | clinicaltrials |
| NCT00536341 | Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 / Phase 2 | 64 | SCRI Development Innovations, LLCOTHER | 1 | Jan 16, 2017 | clinicaltrials |
| NCT00477035 | Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies | completed | Phase 1 | 22 | Sally AraiOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT00091624 | A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) | completed | Phase 1 | 77 | Celgene CorporationINDUSTRY | 1 | Dec 1, 2016 | clinicaltrials |
| NCT00930514 | A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma | completed | Phase 1 | 281 | Hoffmann-La RocheINDUSTRY | 22 | Nov 2, 2016 | clinicaltrials |
| NCT01122875 | A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma | completed | Phase 1 | 14 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Sep 7, 2017source: clinicaltrials